BlossomHill Therapeutics, Inc. Stock

Stocks

Market Closed - Nasdaq 04:00:00 2026-08-28 pm EDT			5-day change	1st Jan Change
19.56 ^USD	-1.21%		+19.41%	-

Aug. 18	BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer	MT
Aug. 18	Blossomhill Therapeutics Receives Fda Fast Track Designation for Bh-30643 for Treatment of Advanced Egfr C797s-Positive Nsclc	CI

Aug. 18	BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer	MT
Aug. 18	Blossomhill Therapeutics Receives Fda Fast Track Designation for Bh-30643 for Treatment of Advanced Egfr C797s-Positive Nsclc	CI
Aug. 11	BlossomHill Therapeutics Insider Bought Shares Worth $5,000,000, According to a Recent SEC Filing	MT
Aug. 09	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to NASDAQ Composite Index	CI
Aug. 07	BlossomHill Therapeutics Shares Fall in Nasdaq Debut	MT
Aug. 07	BlossomHill Therapeutics Prices Upsized Nasdaq IPO	MT
Aug. 06	BlossomHill Therapeutics, Inc. has completed an IPO in the amount of $150 million.	CI
Jul. 17	BlossomHill Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 21	BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting	CI

Aug. 19	BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC	AQ
Aug. 18	BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC	GL
Aug. 06	BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering	AQ

1 day	-1.21%
1 week	+19.41%

Manager	Title	Age	Since
Jing Rong Jean Cui CEO	Chief Executive Officer	62	2020-05-31
Jason Keyes DFI	Director of Finance/CFO	55	2025-04-30
Zachary Zimmerman CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jing Rong Jean Cui BRD	Director/Board Member	62	2020-05-31
Bihua Chen BRD	Director/Board Member	57	2021-01-31
Yi Shan Li CHM	Chairman	61	2020-05-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/10/26	Sundeep Agrawal	Conversion	Director	1,157,048	3.7781%
8/10/26	Cormorant Asset Management LP	Conversion	Company	6,915,568	22.5815%
8/10/26	Vincent Liptak	Buy	General Counsel	47,574	0.1553%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BLOSSOMHILL THERAPEUTICS, INC.	-1.21%	+19.41%	-	-	607M
LONZA GROUP AG	-0.78%	-1.42%	+2.49%	+22.78%	51.14B
REVOLUTION MEDICINES, INC.	-6.00%	-0.75%	+442.41%	+544.39%	47.4B
IQVIA HOLDINGS INC.	-0.24%	+0.74%	+38.69%	+18.02%	43.19B
BEONE MEDICINES AG	-1.55%	-2.07%	+23.08%	+81.47%	42.35B
CELLTRION, INC.	-0.31%	-0.83%	+16.15%	+51.42%	33.23B
MEDPACE HOLDINGS, INC.	-1.79%	-3.24%	+27.00%	+129.56%	17.07B
ASCENDIS PHARMA A/S	-0.58%	-2.12%	-	-	16.38B
EUROFINS SCIENTIFIC SE	-0.88%	-0.66%	+11.60%	+27.75%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.66%	-1.25%	+78.59%	+46.66%	14.15B
Average	-1.50%	+2.00%	+80.00%	+115.26%	28.03B
Weighted average by Cap.	-1.74%	+0.39%	+98.85%	+137.44%